Limitations of conventional dopaminergic medication in advanced Parkinson’s disease: results from 127 patients treated with Levodopa Carbidopa Intestinal Gel
Objective: To evaluate the characteristics of the last conventional dopaminergic treatments in a large cohort of patients with advanced Parkinson’s Disease (APD) treated with Levodopa…Cellular Modeling of Tyrosine Hydroxylase Deficiency Recapitulates Patient Phenotypes and Response to Treatment.
Objective: Characterize a new cellular model of Tyrosine Hydroxylase deficiency (THD) based on induced pluripotent stem cells (iPSCs) to better understand the pathophysiology and test…Three-year safety and clinical outcomes from the PD-1101 trial of AADC gene therapy for advanced Parkinson’s disease
Objective: To present preliminary 3-year data from the PD-1101 trial of VY-AADC01 for advanced Parkinson’s disease (PD) with motor fluctuations. Background: This 3-year phase 1b…Effectiveness of Carbidopa/Levodopa Enteral Suspension (CLES) in Advanced Parkinson’s Disease (APD) Patients with Moderate to Severe Fatigue: Sub-group Analysis from PROviDE study
Objective: To examine the effect of CLES at 12 months of follow-up in APD patients with moderate to severe fatigue. Background: Fatigue, one of the…Inhaled levodopa (LD) as a treatment for Parkinson’s disease (PD) patients in an emergency setting
Objective: To report on use of CVT-301 (inhaled LD) to treat PD patients with complicated OFF period symptoms who present to the emergency department (ED).…Nurse led intrajejunal levodopa pathway for a regional neurosciences centre
Objective: To evaluate the impact of introducing a nurse led advanced therapy service for patients referred for levodopa/carbidopa intestinal gel (LCIG). Background: Leeds Teaching Hospitals…CVT-301 treatment provides consistent and clinically significant improvements in Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) over 12 weeks
Objective: A post hoc analysis of UPDRS-III sequential changes over the 12-week treatment period of a phase 3 study. Background: CVT-301 is an inhaled levodopa…Accounting for unmeasured confounders in treatment response: a comparison of levodopa versus non-levodopa dopaminergic drugs
Objective: To compare short-term levodopa and non-levodopa dopaminergic treatment response in people with Parkinson’s disease (PD) using instrumental variable analysis and linear regression. Background: Treatment…Apomorphine as a Diagnostic tool to Identify Levodopa Responsive Atypical Parkinsonism
Objective: To assess the efficacy of apomorphine in identification of levodopa responsive atypical parkinsonism. Background: Management of atypical parkinsonism is a challenge. Most of these…Characteristics of prescribers for Parkinson’s disease patients: A nationwide study on 2017 Medicare data
Objective: To assess characteristics of Medicare prescribers for Parkinson’s disease (PD) patients, as a target population for delivering advanced PD care education. Background: PD is…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 57
- Next Page »